Pioneering Methods in Brain Optimization and Mental Health Treatment.
ACS Medicinal Chemistry Letters March 14, 2024 DOI: 10.1021/acsmedchemlett.4c00058 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | AI-driven non-invasive neurostimulation N-isopropyl tryptamines tryptamine derivatives psilocybin psilocin |
| Keywords | Psychedelics Artificial intelligence Brain stimulation Mental health |
| Key findings | AI-driven non-invasive neurostimulation and tryptamine derivatives show promise for personalized brain therapy and mental health treatment. |
Abstract
This Patent Highlight explores ground-breaking advancements in neurostimulation, psychedelic therapy, and brain function optimization from recent innovations. It examines methods for altering brain states through AI-driven non-invasive neurostimulation, potentially contributing to personalized brain therapy. The publication also delves into the therapeutic potential of N-isopropyl tryptamines and tryptamine derivatives. Furthermore, it discusses the therapeutic applications of psilocybin and psilocin crystalline forms in mental health and central nervous system disorders. By comparing and contrasting these diverse approaches, this work highlights their mechanistic insights, therapeutic implications, and contributions to the evolving fields of neuroscience and mental health.
Citations in the library
Cites 3
- The mechanistic divide in psychedelic neuroscience: An unbridgeable gap? Neurotherapeutics January 25, 2024
- Older adults in psychedelic-assisted therapy trials: A systematic review Journal of Psychopharmacology 2024
- The development of psilocybin therapy for treatment-resistant depression: an update BJPsych Bulletin June 26, 2023